|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||16.88 - 17.51|
|52 Week Range||7.27 - 18.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.33|
Stock Research Monitor: ILMN, NXTM, and SIEN LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want a free Stock Review on VLRX sign up now at www.wallstequities.com/registration . For today, WallStEquities.com ...
On a per-share basis, the Santa Barbara, California-based company said it had a loss of 99 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
Achieves Highest Net Sales in Company’ s History. Received FDA Approval of PMA Supplement. Launched OPUS™ Branded Breast Products and miraDry fresh™ Enhanced Protocol.
Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced the closing of its previously announced underwritten public offering of 7,407,408 shares of its common stock, as well as 1,111,111 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters. All of the shares were sold by Sientra. The shares were sold at a public offering price of $13.50 per share and Sientra estimates the aggregate net proceeds to the Company will be approximately $107.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses.
SANTA BARBARA, Calif., May 04, 2018-- Sientra, Inc., a medical aesthetics company, announced today that the Company will release its first quarter 2018 financial results on Wednesday, May 9, 2018 after ...
Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced the upsizing and pricing of its previously announced underwritten public offering. The Company will sell 7,407,408 shares of its common stock at a public offering price of $13.50 per share. The gross proceeds to Sientra, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $100 million.
SANTA BARBARA, Calif., April 30, 2018-- Sientra, Inc., a medical aesthetics company, today announced that it has commenced an underwritten public follow-on offering of approximately $75,000,000 of its ...
Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced its participation at the 2018 Aesthetic Meeting being held at the Jacob K. Javits Convention Center in New York from April 26 – May 1. The Company will be showcasing both its OPUS branded breast products (booth #405) and new miraDry fresh™ procedure which reduces underarm sweat, odor and hair (booth #249). The Company also unveiled its new, best-in-category Sientra Platinum20™ Product Replacement and Limited Warranty Program for the OPUS line of silicone gel breast implants – the only brand of silicone gel breast implants sold exclusively to board-certified and board-eligible plastic surgeons. Additionally, the Company announced preliminary unaudited net sales for the first quarter 2018 of approximately $14.5 million.
Jeffrey M. Nugent, Chairman and Chief Executive Officer of Sientra, commented, “This FDA approval allows us to commercialize our OPUS-branded breast implants with an improved manufacturing process and represents a critical milestone for Sientra.
NEW YORK, April 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
The Santa Barbara, California-based company said it had a loss of 92 cents per share. The breast implant maker posted revenue of $11.1 million in the period. For the year, the company reported that its ...
Remains on Track for Full and Final FDA Approval for U.S. Received ISO 13485 Certification for Breast Implants and Tissue Expanders. Advanced miraDry Integration and Optimization Strategy.
NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Sientra, Inc. (NASDAQ: SIEN ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 13, 2018, at 4:30 PM Eastern Time. To ...
SANTA BARBARA, Calif., March 02, 2018-- Sientra, Inc., a medical aesthetics company, announced today that the Company will release its fourth quarter and full year 2017 financial results on Tuesday, March ...
After looking at Sientra Inc’s (NASDAQ:SIEN) latest earnings announcement (30 September 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sientra, Inc. Here are 5 ETFs with the largest exposure to SIEN-US. Comparing the performance and risk of Sientra, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Sientra, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Sientra, Inc. – DENTSPLY SIRONA, Inc., Zimmer Biomet Holdings, Inc., West Pharmaceutical Services, Inc. and Glaukos Corp (XRAY-US, ZBH-US, WST-US and GKOS-US) that have also reported for this period. ... Read more (Read more...)